Klin Farmakol Farm. 2022;36(4):129-135 | DOI: 10.36290/far.2022.021

The importance of therapeutic drug monitoring in acyclovir dosage optimization

Ivana Kacířová1, 2, Romana Uřinovská1, Jiří Sagan3
1 Oddělení klinické farmakologie, Ústav laboratorní medicíny, Fakultní nemocnice Ostrava
2 Ústav klinické farmakologie, Lékařská fakulta, Ostravská univerzita
3 Klinika infekčního lékařství, Fakultní nemocnice Ostrava

Acyclovir is an antiviral drug used to prevent and treat infections caused by herpes viruses such as herpes simplex virus and varicella-zoster virus. It is intracellularly phosphorylated into triphosphate nucleotides that inhibits viral DNA polymerase. Approximately 5-15 % of acyclovir is metabolized to the main metabolite 9-(carboxymethoxymethyl) guanine (CMMG), the main route of acyclovir elimination is renal excretion, which involves glomerular filtration and active tubular secretion. Accumulation of acyclovir and CMMG may occur in patients with impaired renal function. Acyclovir is often used and has good general tolerance, however, it can cause systemic adverse effects such as nephrotoxicity and neurotoxicity. Preexisting kidney disease, older age, obesity, hypertension, longer duration of treatment, and concurrent use of nephrotoxic drugs are associated with an increased risk of acyclovir-induced nephrotoxicity. The most characteristic symptoms of neurotoxicity are confusion, somnolence, and hallucinations. Symptoms of neurotoxicity caused by acyclovir treatment may be misinterpreted as symptoms of herpetic encephalitis. Accurately distinguishing between these two causes of neuropsychiatric symptoms is particularly important given the different treatment strategies. Determination of CMMG serum concentrations can help to differentiate between neuropsychiatric side effects of acyclovir and symptoms of any form of encephalitis. The wide interindividual variability of acyclovir pharmacokinetics can lead not only to toxicity but also to suboptimal therapeutic concentrations of acyclovir in severe herpes viruses infections. Therapeutic monitoring of acyclovir and CMMG can be a useful tool for optimizing pharmacotherapy with this antiviral, especially in patients with severe clinical conditions.

Keywords: acyclovir, 9-(carboxymethoxymethyl) guanine, concentrations, monitoring.

Accepted: February 8, 2023; Published: February 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kacířová I, Uřinovská R, Sagan J. The importance of therapeutic drug monitoring in acyclovir dosage optimization. Klin Farmakol Farm. 2022;36(4):129-135. doi: 10.36290/far.2022.021.

Download citation

References

  1. Majewska A, Mlynarczyk-Bonikowska B. 40 years after the registration of acyclovir: Do we need new anti-herpetic drugs? Int J Mol Sci. 2022;23(7):3431. Go to original source... Go to PubMed...
  2. Nishii R, Mizuno T, Rehling D, et al. NUDT15 polymorphism influences the metabolism and therapeutic effects of acyclovir and ganciclovir. Nat Commun. 2021;12(1):4181. Go to original source... Go to PubMed...
  3. Brandariz-Nuñez D, Correas-Sanahuja M, Maya-Gallego S, et al. Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases. J Clin Pharm Ther. 2021;46(4):918-926. Go to original source... Go to PubMed...
  4. Abuhelwa Z, Beran A, Venkataramany BS, et al. https://pubmed.ncbi.nlm.nih.gov/35509998/ - affiliation-1 Concurrent nephrotoxicity and neurotoxicity induced by oral valacyclovir in a patient with previously normal kidney function. Cureus. 2022;14(3):e23693. Go to original source... Go to PubMed...
  5. Kacirova I, Urinovska R, Sagan J. Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice. Biomed Pharmacother. 2022;156:113852. Go to original source... Go to PubMed...
  6. Ärlemalm A, Helldén A, Karlsson L, et al. Rapid determination of acyclovir, its main metabolite 9-carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC-MS/MS. Biomed Chromatogr. 2022;36(4):e5315. Go to original source... Go to PubMed...
  7. Sadjadi SA, Regmi S, Chau T. Acyclovir neurotoxicity in a peritoneal dialysis patient: Report of a case and review of the pharmacokinetics of acyclovir. Am J Case Rep. 2018;19:1459-1462. Go to original source... Go to PubMed...
  8. Maximova N, Nisticò D, Luci G, et al. Population pharmacokinetics of intravenous acyclovir in oncologic pediatric patients. Front Pharmacol. 2022;13:865871. Go to original source... Go to PubMed...
  9. Gunness P, Aleksa K, Bend J, et al. Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. Transl Res. 2011;158(5):290-301. Go to original source... Go to PubMed...
  10. Al-Alawi AM, Al-Maqbali JS, Al-Adawi M, et al. Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity. Saudi Pharm J. 2022;30(6):874-877. Go to original source... Go to PubMed...
  11. Helldén A, Odar-Cederlöf I, Larsson K, et al. Death delusion. BMJ. 2007;335(7633):1305. Go to original source... Go to PubMed...
  12. Helldén A, Odar-Cederlöf I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant 2003;18:1135-1141. Go to original source... Go to PubMed...
  13. Helldén A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother. 2006;57(5):945-949. Go to original source... Go to PubMed...
  14. Cotard J. Du délire des négations. Arch Neurol 1882;4:152-170, 282-296.
  15. Robertson KM, Harvey CL, Cunningham JM. Acyclovir-induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report. J Med Case Rep. 2020;14(1):156. Go to original source... Go to PubMed...
  16. Abdalla S, Briand C, Oualha M, et al. Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens. Anti­microb Agents Chemother. 2020;64(12):e01426-20. Go to original source... Go to PubMed...
  17. Abdul-Aziz MH, Alffenaar JWC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020;46(6):1127-1153. Go to original source... Go to PubMed...
  18. Cies JJ, Moore WS, Miller K, et al. Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy. Pharmacotherapy. 2015;35(2):229-233. Go to original source... Go to PubMed...
  19. Euler M, Axelsson G, Helldén A. Differential diagnosis of central nervous system involvement in a patient treated with acyclovir. Ther Drug Monit. 2013;35(4):417-419. Go to original source... Go to PubMed...
  20. Lycke J, Andersen O, Svennerholm B, et al. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother. 1989;24(6):947-954. Go to original source... Go to PubMed...
  21. Yang HH, Hsiao YP, Shih HC, et al. Acyclovir-induced neuropsychosis successfully recovered after immediate hemodialysis in an end-stage renal disease patient. Int J Dermatol. 2007;46(8):883-884. Go to original source... Go to PubMed...
  22. Schulz M, Schmoldt A, Andresen-Streichert H, et al. Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care. 2020;24(1):195. Go to original source... Go to PubMed...
  23. Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis. 1988;157(2):385-388. Go to original source... Go to PubMed...
  24. Urinovska R, Kacirova I, Sagan J. Determination of acyclovir and its metabolite 9-carboxymethoxymethylguanide in human serum by ultra-high-performance liquid chromatography-tandem mass spektrometry. J Sep Sci. 2021;44(16):3080-3088. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.